-
Tytuł:
-
Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants.
-
Autorzy:
-
Chilengi R; Centre for Infectious Disease Research in Zambia, Zambia.
Mwila-Kazimbaya K; Centre for Infectious Disease Research in Zambia, Zambia.
Chirwa M; Centre for Infectious Disease Research in Zambia, Zambia.
Sukwa N; Centre for Infectious Disease Research in Zambia, Zambia.
Chipeta C; Centre for Infectious Disease Research in Zambia, Zambia.
Velu RM; Centre for Infectious Disease Research in Zambia, Zambia.
Katanekwa N; Centre for Infectious Disease Research in Zambia, Zambia.
Babji S; The Wellcome Trust Research Laboratory, Vellore, India.
Kang G; The Wellcome Trust Research Laboratory, Vellore, India.
McNeal MM; Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Meyer N; Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Gompana G; PATH, India.
Hazra S; PATH, India.
Tang Y; PATH, USA.
Flores J; PATH, USA.
Bhat N; PATH, USA.
Rathi N; PATH, India. Electronic address: .
-
Źródło:
-
Vaccine [Vaccine] 2021 Jun 16; Vol. 39 (27), pp. 3633-3640. Date of Electronic Publication: 2021 May 12.
-
Typ publikacji:
-
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Amsterdam, The Netherlands : Elsevier Science
Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
-
MeSH Terms:
-
Rotavirus*
Rotavirus Infections*/prevention & control
Rotavirus Vaccines*/adverse effects
Antibodies, Viral ; Humans ; Immunogenicity, Vaccine ; India ; Infant ; Infant, Newborn ; Vaccines, Attenuated/adverse effects ; Zambia
-
References:
-
J Infect Dis. 2009 Aug 1;200(3):421-9. (PMID: 19545211)
Clin Infect Dis. 2016 May 1;62 Suppl 2:S96-S105. (PMID: 27059362)
Vaccine. 2019 Jul 18;37(31):4407-4413. (PMID: 31178377)
Vaccine. 1998 Feb;16(4):381-7. (PMID: 9607059)
Clin Infect Dis. 2016 May 1;62 Suppl 2:S183-7. (PMID: 27059354)
Vaccine. 2014 May 23;32(25):3094-100. (PMID: 24704505)
JAMA Pediatr. 2018 Oct 1;172(10):958-965. (PMID: 30105384)
Lancet. 2014 Jun 21;383(9935):2136-43. (PMID: 24629994)
Vaccine. 2019 May 1;37(19):2554-2560. (PMID: 30955982)
Stat Med. 1985 Apr-Jun;4(2):213-26. (PMID: 4023479)
Vaccine. 2014 Aug 11;32 Suppl 1:A110-6. (PMID: 25091663)
Hum Vaccin Immunother. 2018 Jul 3;14(7):1791-1799. (PMID: 29543547)
Heliyon. 2017 May 16;3(5):e00302. (PMID: 28560356)
Pediatrics. 2016 Feb;137(2):e20152603. (PMID: 26823540)
J Infect Dis. 2004 Jun 15;189(12):2290-3. (PMID: 15181577)
-
Contributed Indexing:
-
Keywords: Immunogenicity; ROTAVAC; ROTAVAC 5D; Rotavirus Vaccine; Safety; Zambia
-
Substance Nomenclature:
-
0 (Antibodies, Viral)
0 (Rotavirus Vaccines)
0 (Vaccines, Attenuated)
-
Entry Date(s):
-
Date Created: 20210516 Date Completed: 20210708 Latest Revision: 20220531
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8204902
-
DOI:
-
10.1016/j.vaccine.2021.04.060
-
PMID:
-
33992437
-
Background and Aims: ROTAVAC® (frozen formulation stored at -20 °C) and ROTAVAC 5D® (liquid formulation stable at 2-8 °C) are rotavirus vaccines derived from the 116E human neonatal rotavirus strain, developed and licensed in India. This study evaluated and compared the safety and immunogenicity of these vaccines in an infant population in Zambia.
Methods: We conducted a phase 2b, open-label, randomized, controlled trial wherein 450 infants 6 to 8 weeks of age were randomized equally to receive three doses of ROTAVAC or ROTAVAC 5D, or two doses of ROTARIX®. Study vaccines were administered concomitantly with routine immunizations. Blood samples were collected pre-vaccination and 28 days after the last dose. Serum anti-rotavirus IgA antibodies were measured by ELISA, with WC3 and 89-12 rotavirus strains as viral lysates in the assays. The primary analysis was to assess non-inferiority of ROTAVAC 5D to ROTAVAC in terms of the geometric mean concentration (GMC) of serum IgA (WC3) antibodies. Seroresponse and seropositivity were also determined. Safety was evaluated as occurrence of immediate, solicited, unsolicited, and serious adverse events after each dose.
Results: The study evaluated 388 infants in the per-protocol population. All three vaccines were well tolerated and immunogenic. The post-vaccination GMCs were 14.0 U/mL (95% CI: 10.4, 18.8) and 18.1 U/mL (95% CI: 13.7, 24.0) for the ROTAVAC and ROTAVAC 5D groups, respectively, yielding a ratio of 1.3 (95% CI: 0.9, 1.9), thus meeting the pre-set non-inferiority criteria. Solicited and unsolicited adverse events were similar across all study arms. No death or intussusception case was reported during study period.
Conclusions: Among Zambian infants, both ROTAVAC and ROTAVAC 5D were well tolerated and the immunogenicity of ROTAVAC 5D was non-inferior to that of ROTAVAC. These results are consistent with those observed in licensure trials in India and support use of these vaccines across wider geographical areas.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
